Current clinical studies and our clinical practice experience indicate that NMOSD is a more serious clinical condition than MS. [3] Since MS is a completely different pathophysiological process from NMOSD, the treatment strategies differ meaningfully. Some MS immunotherapies appear to aggravate NMOSD conditions; therefore, correct initial diagnosis is crucial for diseases management. Because the initial diagnoses in clinical practice are difficult due to the similarities in patients' presentation with the two disease groups, we summarized the CSF features combined with clinical, magnetic resonance imaging (MRI), and serum characteristics in Chinese patients with MS and NMOSD to provide clues for differential diagnosis.
Methods

Patients and diagnostic criteria
Totally 175 consecutive patients with CNS IIDDs hospitalized in Xuanwu Hospital, Capital Medical University (China) from November 2012 to May 2014 were enrolled in this study. MS was diagnosed based on the latest McDonald criteria. [4] The 2015 Updated International Consensus on Diagnostic Criteria for NMOSDs is used for diagnosing NMOSD. [5] The patients' serum and CSF tests, image findings, and clinical information were retrospectively collected. The study was approved by the Ethnical Committee of Xuanwu Hospital, Capital Medical University.
Magnetic resonance imaging scans
All the brain and spinal MRI were performed on 3.0-T scanners, including axial/sagittal T2-weighted images and T1-weighted images, with or without gadolinium enhancement. The brain scans included axial fluid-attenuated inversion recovery as well.
Cerebrospinal fluid and serum tests
The CSF and serum tests in each group included aquaporin-4-antibodies (AQP4-Ab), myelin oligodendrocyte glycoprotein antibodies (MOG-Ab), myelin basic protein (MBP), specific oligoclonal bands (SOBs), total white blood cell count in CSF, and CSF biochemistry examination.
An enzyme-linked immunosorbent assay (ELISA) was performed to detect CSF and serum antibodies against MOG, with 0.56 and 0.64 as the cutoff values of positivity for CSF and serum, respectively. Cell-based assays (CBAs) were used to detect AQP4-Ab. The immunoenzymatic technique was performed to measure MBP.
Statistical analysis
Categorical variables were expressed as count (percentage) and analyzed by the Chi-square test. Continuous variables were expressed as median (interquartile range [IQR]) due to nonnormal distribution and analyzed by Wilcoxon rank sum test. All statistical analyses were performed using the SAS 9.4 (SAS Institute, Cary, NC, USA). All reported P values are two-sided. P < 0.05 was considered to be statistically significant.
Results
Clinical characteristics
The 175 patients with CNS IIDDs included 85 MS patients (49%) and 90 NMOSD patients (51%) [ Table 1 ]. They were 124 (71%) women and 51 (29%) men. The overall demographic characteristics of the two groups were similar, with no significant differences in gender or age observed [ Table 1 ].
Twenty-two patients (13%) had autoimmune diseases, including Behcet's disease, Hashimoto's thyroiditis, allergic asthma, Sjogren syndrome, Crohn's disease, idiopathic thrombocytopenic purpura, and connective tissue disease (CTD). Fewer MS patients (6%) had autoimmune diseases compared to NMOSD (19%) (χ 2 = 6.9, P < 0.01). Paralysis, anesthesia, and decreased eyesight were the most common symptoms among the 175 patients. Aquaporin-4-antibody detection in cerebrospinal fluid and serum AQP4-Ab in CSF and serum was detected from 131 (75%) patients. Totally 47 patients were positive for serum AQP4-Ab by immunohistochemistry: none with MS and 47 with NMOSD ( χ 2 = 63.9, P < 0.01); while thirty patients were positive for CSF AQP4-Ab: none with MS, thirty patients with NMOSD (χ 2 = 36.4, P < 0.01).
Specific oligoclonal bands in cerebrospinal fluid
CSF-SOB frequency in patients with MS was 59%, while it was only 20% with NMOSD ( χ 2 = 25.7, P < 0.01). 
Myelin basic protein in cerebrospinal fluid
Magnetic resonance imaging findings
In the MS group, 79 patients had available brain MRI results [ Figure 1a and 1b]. 
dIscussIon
In this single-center study, we analyzed the clinical, radiological, serum, and CSF findings of patients with CNS demyelinating disease; those were diagnosed as MS and NMOSD at Xuanwu Hospital, Capital Medical University, China.
Females are more prominent in the two kinds of diseases, and this character is more remarkable in NMOSD (female to male ratio was 1.9-7.3:1.0) compared to MS (female to male ratio was 2.57-2.62:1.0). [6, 7] Our results in gender ratio failed to reach statistical difference between groups, possibly due to the limited power or potential selection bias. Although both diseases have a female predominance, in most western studies, AQP4-positive NMOSD patients have a female to male ratio between 8 and 9 to 1. [8] [9] [10] Typically, a distinguishing feature of NMOSD is the later age of symptom onset; patients with NMOSD are on average 10 years older than patients with MS at disease presentation (mean onset at around four decades for NMOSD and three decades for MS). [11] However, our study did not show a significant difference of age at disease onset in the MS and NMOSD group. The age difference was 4 years; median age of symptoms onset in MS group was 32 years old, while in NMOSD group, it was 36 years old [ Table 1 ]. The possible reason could be that this study included only adult patients, while other studies included the whole population.
There were 38 patients with coexisting autoimmune diseases, including Behcet's disease, Hashimoto's thyroiditis, allergic asthma, Sjogren syndrome, Crohn's disease, idiopathic thrombocytopenic purpura, and CTD. The NMOSD suffered more often from autoimmune diseases than the MS patients with a significant difference. These results are also similar with the previous reports: 20-30% of NMOSD patients have been reported to present accompanying autoimmune disorders, and 40-50% of them have coexisting autoantibodies (organ and not organ specific). [11] In particular, AchR-Abs (antibodies against acetylcholine receptor) might serve as a red flag in the differential diagnosis of NMOSD and MS. [12] Although that NMOSD tends to be associated with autoimmune diseases is not fully understood, multiple evidence of the humoral mechanisms in NMOSD lesions were reported. [13] The primary purpose of the study was to describe the CSF findings in Chinese NMOSD and MS patients at a single site. Slight elevation of CSF protein levels (450-700 mg/L) has been reported in MS patients, while CSF protein level in NMOSD was elevated up to 2900-6400 mg/L during relapses and stayed between 330 and 630 mg/L at the remission phase. [1] CSF protein level was slightly elevated than normal, with average 400 mg/L in MS group and average 483 mg/L in NMOSD group in our findings. CSF pleocytosis is present in around 50% of NMOSD samples. [1] NMO CSF white cell is usually ≥50 × 10 6 /L, while in MS it is <50 × 10 6 /L. [3, 14] However, in our study, mean CSF white cell was 10.6 × 10 6 /L in NMOSD group and 7.8 × 10 6 /L in MS group. No significant difference was found between groups regarding CSF white cell count, CSF protein, CSF glucose, or CSF chloride levels. These results may be distinct characteristics of the Chinese population, but this hypothesis still needs to be confirmed by multiple sites studies with larger sample sizes. Total CSF white cell counts and CSF protein levels were generally consistent with what reported previously, [1] except for the CSF protein level and white cell count in NMOSD during relapses which were lower. [1] The levels of CSF white cell counts and CSF protein were slightly elevated than the normal range, indicating inflammatory activity during relapses. Serum AQP4-Ab positivity was significantly higher in NMOSD (67%) than MS patients (0) (P < 0.001), which is consistent with previous studies. [11] Immunopathological data support the AQP4-Ab association with NMOSD, [11] which is necessary for diagnosing NMOSD. [5] Seventeen patients with NMOSD had AQP4-Ab positive in serum, but negative in CSF. In other words, AQP4-Ab was detectable in 64% CSF samples from AQP4-Ab seropositive patients with NMOSD and in none of the CSF samples from seronegative patients. Therefore, testing for CSF AQP4-Ab did not improve the sensitivity or specificity of NMOSD diagnosis. [15] The most updated guideline on NMOSD diagnosing also indicate that routine CSF testing of AQP4-Ab-seronegative patients is not recommended, [5] except in cases with additional confounding serum autoantibodies leading to uninterpretable or false-positive assay results where CSF testing may be considered.
CSF-oligoclonal band (CSF-OB) frequency over 90% of MS patients has been demonstrated in western countries, while approximately 60% in Asia. [1] In our findings, CSF-OB frequency in MS patients was 59%, which was lower than western countries (90%); it is consistent with Asian patients' characteristics (around 60%). Low positivity might involve with ethnic or race issues. CSF-OBs, regarded as a hallmark of MS, were present in 20% of our NMOSD patients. In accordant with the reports, the detection rate of CSF-OB in NMOSD patients is around 15-30%, which is thought to be transient. [1] A follow-up study is requisite to demonstrate the rate of CSF-OB changes among NMOSD patients. Thus, the presence or absence of OBs is one of the most helpful parameters in differentiating NMOSD from MS; MOG is a target of autoantibodies in animal models of inflammatory demyelinating diseases of the CNS, such as MS. [16] The role of MOG-Abs in diseases pathogenesis is unclear. [5] Kim et al. found a strong predilection of MOG-Abs for optic nerve and less for the spinal cord, unlike AQP4-Abs, which showed opposite preferences. [17] MOG-Abs were mainly present in our MS patients. Previous studies indicate MOG-Abs tended to exist in younger patients, less frequently female, and less likely to relapse in comparison to NMOSD patients with AQP4-Ab. [18, 19] High-titer MOG-Abs are present in pediatric patients but rarely in adults. [16] In this study, the median age of serum MOG-IgG positive patients was 26.5 years in NMOSD group, while MS patients were elder to have serum MOG-IgG positivity (median age was 32 years).
Another striking observation is that the patients with solely MOG-IgG present in their serum have better clinical outcomes (data not shown). Further studies are needed to confirm this observation and determine whether MOG-Ab would be useful in the differential diagnosis of patients with IIDDs, especially those both negative for CSF-SOB and serum AQP4-Ab. The brain lesions in MS are nonspecific or indistinguishable from NMOSD lesions in general, while some NMOSD abnormalities may be parallel midline AQP4-rich regions, such as the hypothalamus and periaqueductal brainstem regions surrounding the ventricular system. The presence of lateral ventricular, juxtacortical, infratentorial, and brain stem lesions was more significant in our MS than NMOSD patients; those typical lesions would attribute to the diagnosis of MS. [4] The spinal cord lesions in NMOSD are typically located centrally and extend over three or more contiguous vertebral segments, the spinal cord lesions in MS tend to be shorter (less than one vertebral segment in length). Long vertebral spinal lesions are a hallmark for diagnosis of NMOSD in consistence with updated guideline. [5] In general, in the study, higher female ratio is found in NMOSD than MS even without significance. Patients with NMOSD may be older at symptoms onset, while MS patients may be slightly younger (the difference did not reach the significant level). Systemic autoimmune diseases are more common in NMOSD. No distinct differences were found in routine CSF testing or biochemistry testing between groups. Serum AQP4-Ab positivity and CSF-OB are remarkably different between the NMOSD and the MS. MOG-IgG positivity tends to be seen in younger patients with MS. The potential role of MOG-Abs in CSF-SOB and serum AQP4-Ab double-negative patients needs to be investigated.
There are some limitations in this study. First, the follow-up of patients is lacking. Second, as CBAs for MOG-Abs detection are still not available in our city, we had to perform ELISA to detect the antibodies against CSF and serum MOG-Abs. [16] Third, the study is a retrospective single-site descriptive study that causes a possible geographic bias even though the patients are from multiple provinces in China. A multiple-site study would be performed in the future to describe CSF findings, as well as the clinical manifestations and radiological characteristics of patients with CNS IIDDs in China. 
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